Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Published: 8th May 2017
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Although transarterial chemoembolization is recommended as the standard treatment for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma (
The nationwide multicentre database of the Korean Liver Cancer Association was reviewed. Patients with
Among 887 randomly selected patients with
Treatment strategies that include liver resection offer a survival benefit compared with non‐surgical treatments for potentially resectable
You may also be interested in
Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Authors: S. D. Nelen, M. van Putten, V. E. P. P. Lemmens, K. Bosscha, J. H. W. de Wilt, R. H. A. Verhoeven et al.
Notes: Less surgery, more chemo, but no change in survival
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better
Authors: D. W. Kjaer, H. Larsson, L. B. Svendsen, L. S. Jensen
Notes: Better short term outcome
Randomized clinical trial
Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy.
Authors: M. Scarpa, E. Pinto, E. Saraceni, F. Cavallin, M. Parotto, R. Alfieri et al.
Notes: Psychologists improve postoperative sleep
Adaptation of the By‐Band randomized clinical trial to By‐Band‐Sleeve to include a new intervention and maintain relevance of the study to practice. BJS 2017; 104: 1207-1214.
Authors: C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
Notes: Something to consider
Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.
Authors: F. J. C. ten Kate, S. H. van Olphen, M. J. Bruno, B. P. L. Wijnhoven, J. J. B. van Lanschot, L. H. J. Looijenga et al.
Notes: Useful biomarker especially for early disease
Authors: J. Thereaux, T. Lesuffleur, M. Païta, S. Czernichow, A. Basdevant, S. Msika et al.
Notes: Poor follow up despite international guidelines
Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. BJS 2017; 104: 1131-1140.
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
Notes: Only different in short term
Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Notes: No evidence for best treatment